Mr. Louis Laflamme reports

OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS

The Superior Court of Quebec issued a final order today in connection with the previously announced acquisition by Haemonetics Corp. of all of the issued and outstanding common shares in the capital of Opsens Inc. for $2.90 in cash per share, pursuant to a statutory plan of arrangement under the Business Corporations Act (Quebec).

It is anticipated that the arrangement will be completed on or about Dec. 12, 2023, subject to the satisfaction of customary closing conditions. It is expected that trading of the shares will cease in the public market, and the shares will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX designation, and that the corporation will apply to cease to be a reporting issuer under Canadian securities laws, in each case shortly after completion of the arrangement.

The terms of the arrangement and the arrangement agreement between the corporation, Haemonetics and 9500-7704 Quebec Inc., dated Oct. 10, 2023, are further described in the management information circular and related materials for the special meeting of shareholders of the corporation held in connection with the arrangement, all of which are available under the corporation's profile on SEDAR+.

About Opsens Inc.

Opsens focuses mainly on cardiology. The corporation offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the Optowire, is a second-generation fibre optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The Optowire has been used in the diagnosis and treatment of more than 250,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan and Canada.

Opsens has received FDA (Food and Drug Administration) clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement procedures (TAVR). This unique guidewire is a three-in-one solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.

Opsens's SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to leave the hospital earlier, sometimes the same day. The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is expected to reach over 400,000 in 2025 and over 600,000 in 2030.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.